Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082418 | 0.78 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL377365 | 0.73 | MEN1 (0.39) | MEN1KMT2AOPRM1OPRK1OPRL1 | |
| SCHEMBL9541911 | 0.70 | MEN1 (0.46) | MEN1KMT2ACYP2D6 | |
| SCHEMBL377463 | 0.68 | MEN1 (0.35) | MEN1KMT2AOPRL1 | |
| SCHEMBL5078420 | 0.66 | MEN1 (0.46) | MEN1KMT2AOPRM1OPRK1OPRL1 | |
| SCHEMBL5080028 | 0.66 | MEN1 (0.46) | MEN1KMT2AOPRM1OPRK1OPRL1 | |
| SCHEMBL3310454 | 0.66 | MEN1 (0.46) | MEN1KMT2AOPRM1OPRK1OPRL1 | |
| SCHEMBL11040986 | 0.64 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL11064104 | 0.62 | ALDH1A1 (0.46) | MEN1KMT2AOPRM1OPRK1OPRL1 | |
| SCHEMBL6439975 | 0.62 | OPRL1 (0.44) | MEN1KMT2ASMN1; SMN2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7129367-B2 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1592698-A2 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | Takasago International Corporation (JP) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004072088-A2 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | SQLE, C9, PHOSPHO1 | MEN1 460/4885KMT2A 2194/4885CYP2D6 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.